Hereditary angioedema oral options reach maturity

Hereditary angioedema has had injectable lanadelumab and C1 esterase inhibitor concentrate as the modern prophylaxis options. Berotralstat established oral once-daily prophylaxis, and follow-on oral plasma kallikrein inhibitor programs (sebetralstat for on-demand and others) are reaching late-stage data. Factor XIIa inhibitor programs are entering pivotal trials. The category has gone from injectable-only to oral-and-modern in three years.